司美格鲁肽治疗多囊卵巢综合征伴胰岛素抵抗60例临床分析

Clinical Analysis of Semaglutide in Treatment of 60 Cases Polycystic Ovary Syndrome with Insulin Resistance

目的探讨GLP-1受体激动剂(司美格鲁肽)治疗具有胰岛素抵抗的多囊卵巢综合征(PCOS-IR)不孕患者临床疗效。方法选取60例胰岛素抵抗的PCOS-IR不孕症患者,随机分为观察组(应用司美格鲁肽治疗)和对照组(应用二甲双胍治疗),每组30例。比较治疗前后两组患者血清中性激素、胰岛素、血糖、糖化血红蛋白指标变化情况,包括促卵泡刺激素(FSH)、黄体生成素(LH)、睾酮(T)、催乳素(PRL)、胰岛素(INS)、C-肽、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbAlc)水平,评估用药的有效性。结果治疗前,两组患者性激素、胰岛素、血糖、糖化血红蛋白指标比较差异均无统计学意义(P>0.05);治疗后,两组患者相关指标FPG、FINS、HDMA-IR及HbAlc显著降低(P<0.05)。结论司美格鲁肽能够显著改善PCOS合并IR患者胰岛素抵抗及糖代谢水平,并对改善患者排卵和调整受孕周期有显著疗效。

Objective To investigate the effect of GLP-1 receptor agonist(Semaglutide)in the treatment of polycystic ovary syndrome and infertility with Insulin resistance(PCOS-IR).Method A total of 60 patients with PCOS-IR,infertility and Insulin resistance was selected as the subjects,and they were randomly divided into observation group(taking Semaglutide)and control group(taking Metformin),with 30 cases in each group.To compare the changes of hormones,Insulin,blood glucose and HbAIc before and after treatment between the two group.These indexes included FSH,LH,T,PRL,INS,C-peptide,FPG,2 h PG,HbAIc.We evaluated effect-iveness of the drug.Results Before treatment,there was no statistical significance in the sex hormon,Insulin,blood glucose,glycosylated hemoglobin in two groups(P>0.05).After treatment,the values of FPG,FINS,HOMA-IR and HbAIc in two groups decreased comparing with those before treatment(P<0.05).Conclusion Semaglutide decreased the level of Insulin resistance and glucose metabolism in patients with PCOS-IR,and Semaglutide has a significant effect on improving ovulation and adjusting the conception cycle of patients.